Understanding the Market | AIM VACCINE surged over 6% during intraday trading, with institutions expecting the company to launch more than 10 blockbuster products in the coming years

AIM VACCINE's stock price rose over 6% during the trading session, and as of the time of writing, it is up 4.71%, priced at HKD 4, with a trading volume of HKD 8.0917 million. In terms of news, on May 19, AIM VACCINE announced that its mRNA shingles vaccine, after receiving approval from the U.S. FDA to conduct clinical trials in March 2025, has recently obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, with approvals granted in both China and the U.S. Preclinical trial data shows that AIM VACCINE's mRNA shingles vaccine demonstrates significant advantages in key immune indicators. Fosun International Securities previously released a research report stating that AIM VACCINE has successfully commercialized 8 vaccines, including the market-leading rabies vaccine and hepatitis B vaccine, with a sales network covering the entire country and expanding overseas. More importantly, the company has a rich pipeline of 21 vaccines under research, covering five major technology platforms, with over 10 major products expected to be launched between 2025 and 2028. Among them, three key products: PCV13, the iterative acellular rabies vaccine, and PPSV23 have entered the final stages before market launch, and will be successively launched in the next 1-2 years, driving the company's performance to achieve leapfrog growth and value reassessment